



(a business trust constituted on 29 July 2011 and registered on 25 September 2012
under the laws of the Republic of Singapore)
managed by
RHT Health Trust Manager Pte. Ltd.

CHANGES TO THE COMPOSITION OF THE BOARD

RHT Health Trust Manager Pte. Ltd. ("**RHT TM**"), the Trustee-Manager of RHT Health Trust ("**RHT**" or the "**Trust**"), wishes to announce the following changes to the Board of RHT TM with effect from 25 February 2019.

RESIGNATION OF DIRECTORS

1. The resignation of Mr Vivek Mehra as Non-Executive Chairman and Independent Director and his cessation as member of the Nominating Committee.
2. The resignation of Mr Eng Meng Leong as Independent Director and his cessation as Chairman of the Remuneration Committee and member of the Audit and Risk Management Committee.
3. The resignation of Mr Sydney Michael Hwang as Independent Director and his cessation as Chairman of the Nominating Committee and member of the Remuneration Committee.
4. The resignation of Dr Yogendra Nath Mathur as Lead Independent Director and his cessation as member of the Audit and Risk Management Committee and member of the Nominating Committee.
5. The resignation of Mr Peter Joseph Seymour Rowe as Independent Director and his cessation as Chairman of the Audit and Risk Management Committee and member of the Remuneration Committee.
6. The resignation of Mr Daljit Singh as Non-Independent Non-Executive Director.
7. The resignation of Mr Gurpreet Singh Dhillon as Executive Director.

The Independent Directors on the Board of RHT TM are resigning from the Board with effect from 25 February 2019 following a reconstitution of the Board by the shareholder of the Trustee-Manager. This comes after the completion of the disposal of the entire asset portfolio of RHT on 15 January 2019 (the "**Disposal**"), and the distribution of the majority of the net proceeds to Unitholders

In addition, Mr Daljit Singh will be stepping down as Non-Independent and Non-Executive Director with effect from 25 February 2019 to pursue his personal interests.

The Trustee-Manager would like to extend its utmost gratitude and appreciation to the Independent Directors and Mr Daljit Singh for their strong leadership and invaluable contribution to RHT TM and RHT. In particular, without their unwavering support, the Disposal would not have been possible.

RESIGNATION OF CHIEF EXECUTIVE OFFICER

Mr Gurpreet Singh Dhillon, the current Chief Executive Officer ("**CEO**") and Executive Director of RHT TM will resign as Executive Director on the 25 February 2019, and as the CEO with effect from 31 March 2019. Mr Dhillon will also be resigning as Director of THR Infrastructure Pte. Ltd. (formerly Fortis



Global Healthcare Infrastructure Services Pte. Ltd.) and THR Services Pte. Ltd (formerly RHT Health Trust Services Pte. Ltd.) with effect from 31 March 2019.

Mr Gurpreet Dhillon joined RHT TM in 2011 and was appointed its Chief Operating Officer on 1 January 2013. Soon after, he rose to become the CEO of RHT TM on 22 May 2013. During the early years of RHT, Mr Gurpreet Dhillon was instrumental in positioning RHT as an Indian healthcare investment, providing investors with attractive and stable yields. Under his leadership, RHT was one of the best performing business trusts listed on the SGX-ST¹.

Chairman of RHT TM, Mr Vivek Mehra said "The Board appreciates and wishes to thank Gurpreet for his leadership and dedication to RHT and the Company. His stewardship of RHT has been characterised by strategic thinking and tireless efforts to increase the credibility and visibility of RHT among the investment community. We were also fortunate to have Gurpreet lead RHT through the recent challenging times, from which RHT has emerged on top. We wish him all the best for his future endeavours".

Mr Gurpreet Dhillon said "It has been an enriching journey for me with RHT from being the first Indian healthcare trust listed on the SGX-ST, to one of the best performing trusts. While it has been rather eventful in the last couple of years, I am very thankful for the confidence that our investors have shown in us. I would also like to express my gratitude to Board of Directors for the invaluable guidance that they have given me and the team over the years. I look forward to my new endeavours and I wish the Board and management all the best for the future".

APPOINTMENT OF NEW INDEPENDENT DIRECTORS AND RECOMPOSITION OF BOARD COMMITTEES

1. The appointment of Mr Tan Bong Lin as Non-Executive Chairman and Independent Director.
2. The appointment of Dr Ronnie Tan Keh Poo as Independent Director.
3. The appointment of Dr Wong Chiang Yin as Independent Director.

Mr Tan Bong Lin has 27 years of trading, sales, operations and business management experience with investment banks and brokerage firms. He was with Citigroup Global Markets Singapore up till April 2017, where he held the position of Managing Director & Business Manager. He is currently the Lead Independent Director and Chairman of the Audit Committee of Starhill Global REIT as well as the Independent Director and Chairman of the Audit Committee of APAC Realty Limited. Mr Tan holds a Bachelor of Accountancy from the University of Singapore.

Dr Ronnie Tan Keh Poo is a qualified medical doctor and holds a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne as well as a Master of Health Administration from Lorna Linda University. He worked as a medical practitioner in various government and private healthcare facilities in Australia and Singapore. Dr Tan held senior positions in various healthcare institutions such as Parkway Holdings Limited where he was the CEO of Gleneagles Hospital. He was also the CEO of Siloam Gleneagles group of hospitals in Indonesia. Prior to Dr Tan's retirement in May 2017, he held the position of CEO and Executive Director of Bowsprit Capital Corporation (as manager of First Real Estate Investment Trust).

¹ "Business Trusts back in Favour", *Straits Times*, 14 June 2014



Dr Wong Chiang Yin is a public health specialist. He was previously the Executive Director and Group CEO of Cordlife Group Limited (listed on the Singapore Exchange Limited (“SGX”)) and TMC Life Sciences Berhad (listed on the Bursa Malaysia). He is an elected Council Member of the Singapore Medical Association and Academy Medicine Singapore. Dr Wong is currently an Independent Director of Beng Kuang Marine Limited (listed on the SGX). He has held senior positions in the public sector, including Chief Operating Officer of Singapore General Hospital and Changi General Hospital. Dr Wong holds a Masters of Medicine (Public Health) from the National University of Singapore and Masters of Business Administration (Finance) from the University of Leicester.

Please refer to the SGXNET announcements for further details of the appointment of the new Independent Directors.

The Board considers Mr Tan Bong Lin, Dr Ronnie Tan Keh Poo and Dr Wong Chiang Yin to be independent for the purpose of Rule 704(8) of the Listing Manual of the Singapore Exchange Limited.

The Nominating Committee (“NC”) and Remuneration Committee (“RC”) will also be dissolved with effect from 25 February 2019. This comes after the completion of the Disposal on 15 January 2019, where RHT has ceased to have any business operations and has become a cash trust. The responsibilities of the NC and RC will be subsumed under the Audit & Risk Management Committee.

Consequent to the aforesaid changes and with effect from 25 February 2019, the composition of the Board and Board Committees shall be as follows:

BOARD OF DIRECTORS	
Name	Designation
Mr Tan Bong Lin	Non-Executive Chairman and Independent Director
Dr Ronnie Tan Keh Poo	Independent Director
Dr Wong Chiang Yin	Independent Director
Dr Chan Boon Kheng	Non-Executive and Non-Independent Director
Mr Loh Min Jiann	Non-Executive and Non-Independent Director

AUDIT & RISK MANAGEMENT COMMITTEE	
Name	Designation
Dr Ronnie Tan Keh Poo	Chairman of Audit & Risk Management Committee
Mr Tan Bong Lin	Member
Dr Wong Chiang Yin	Member
Mr Loh Min Jiann	Member

<End>



For further details please contact:

Media

FTI Consulting

Tom Evrard: tom.evrard@fticonsulting.com / +65 9850 1998.

Malcolm Robertson: malcolm.robertson@fticonsulting.com / +65 6831 7829

Investors

RHT Investor Relations:

Suan Hui Tan: suanhui.tan@rhealthtrust.com / +65 6603 5779



About RHT Health Trust

RHT is the first business trust with an initial portfolio comprising of healthcare assets in India to be listed on the Main Board of the Singapore Exchange Securities Trading Limited. It completed its disposal of its entire asset portfolio to Fortis Healthcare Limited on the 15 January 2019. Currently RHT's assets comprise mainly of cash.

About the Trustee-Manager - RHT Health Trust Manager Pte. Ltd.

The Trustee-Manager is an indirect wholly-owned subsidiary of Stellant Capital Advisory Services Private Limited ("Stellant"). Stellant is a Category I Merchant Banker registered with Securities and Exchange Board of India ("SEBI") and engaged in Management of Issues, Determination of Financial Structure, Underwriting of Issues, Investment Advisory Services and Corporate Advisory Services, specifically in Healthcare Arena. Stellant is a wholly-owned step down subsidiary of Fortis Healthcare Limited, which is a key integrated healthcare delivery service provider in India with a leading presence in hospital business and diagnostics. Stellant, being engaged in the merchant banking activities primarily focus on imparting advisory services in the "healthcare sector" arena and providing consultancy services across the healthcare delivery services.